Monopar Therapeutics Inc. Profile Avatar - Palmy Investing

Monopar Therapeutics Inc.

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet…

Biotechnology
US, Wilmette [HQ]

Government Awards Analysis Beta

Obligations Over-Time

Awards
Obligations

Monopar Therapeutics Inc. has no obligation with a government/award agency.

Latest Obligations

Contracts
$ 0.0
IDVs
$ 0.0
Direct Payments
$ 0.0
Grants
$ 0.0
Loans
$ 0.0
Other Payments
$ 0.0
vs. Previous FY
Contracts
$ 0.0
IDVs
$ 0.0
Direct Payments
$ 0.0
Grants
$ 0.0
Loans
$ 0.0
Other Payments
$ 0.0

Spending By Type

Awards
Obligations

Monopar Therapeutics Inc. can't present spending by time.

Get PRO Today

With PRO you will unlock all insights related to government awards of Monopar Therapeutics Inc..

End of MNPR's Analysis
CIK: 1645469 CUSIP: 61023L108 ISIN: US61023L1089 LEI: - UEI: -
Secondary Listings
MNPR has no secondary listings inside our databases.